Sarepta Therapeutics Inc to host SRP-9001 Micro-dystrophin R&D Day Transcript
Good day, and welcome to the Sarepta Therapeutics conference call and webcast for the SRP-9001 Micro-dystrophin R&D day. (Operator Instructions) As a reminder, today's program is being recorded.
Now I'd like to turn the call over to Doug Ingram, President and CEO, for opening remarks.
Thank you, Catherine, and good morning, everyone, and thank you for joining us today for what we are calling throughout as Micro-dystrophin Day.
First, remember, we will make a number of forward-looking statements today. Please refer to our various public filings for a list and discussion of the risks and uncertainties that come with making predictions about what may occur in the future. Now in a moment, Dr. Louise Rodino-Klapac will walk us through recent updates from our 3 ongoing studies, the Study 101, Study 102 and Study 103. And then we'll provide information on the protocol for our pivotal trial, Study 301, a study that we call EMBARK.
SRP-9001 represents the most
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
